This study aimed to identify and characterize highly potent and broad-neutralizing antibodies (bnMAbs) against HIV from four HIV-infected donors. The researchers screened the neutralizing antibody repertoires of these donors and isolated 17 new monoclonal antibodies (MAbs) that exhibit broad neutralization across different HIV clades. These new MAbs are significantly more potent than previously described bnMAbs, with some being nearly 10-fold more potent than PG9, PG16, and VRC01, and 100-fold more potent than the original prototype HIV. The study also found that the new MAbs recognize novel epitopes on the envelope glycoprotein gp120, providing new targets for vaccine design. Additionally, the researchers analyzed the neutralization profiles of the MAbs and found that certain combinations of antibodies provide better coverage of the diverse global HIV strains than others, suggesting that these combinations could be useful in active or passive immunization strategies. Overall, the isolation of multiple HIV bnMAbs from different donors that provide broad coverage at low concentrations is a positive step towards the development of an effective antibody-based HIV vaccine.This study aimed to identify and characterize highly potent and broad-neutralizing antibodies (bnMAbs) against HIV from four HIV-infected donors. The researchers screened the neutralizing antibody repertoires of these donors and isolated 17 new monoclonal antibodies (MAbs) that exhibit broad neutralization across different HIV clades. These new MAbs are significantly more potent than previously described bnMAbs, with some being nearly 10-fold more potent than PG9, PG16, and VRC01, and 100-fold more potent than the original prototype HIV. The study also found that the new MAbs recognize novel epitopes on the envelope glycoprotein gp120, providing new targets for vaccine design. Additionally, the researchers analyzed the neutralization profiles of the MAbs and found that certain combinations of antibodies provide better coverage of the diverse global HIV strains than others, suggesting that these combinations could be useful in active or passive immunization strategies. Overall, the isolation of multiple HIV bnMAbs from different donors that provide broad coverage at low concentrations is a positive step towards the development of an effective antibody-based HIV vaccine.